The Blackstone Group, a major US private equity firm, has announced the acquisition of Takeda Consumer Healthcare Company (TCHC), a subsidiary of Takeda Pharmaceutical. Investment funds and other industries have been putting out feelers toward the pharmaceutical sector in recent…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Shionogi, Ping An to Set Up JV in August, Make It a Hub for China/Asia Biz
July 14, 2020
-
BUSINESS Takeda Looks to Derive 70%-Plus of Japan Sales from 5 Focus Areas by FY2025, Revamp HR Systems
July 13, 2020
-
ACADEMIA Avigan Fails to Hit Statistical Significance in COVID-19 Trial: Fujita Health Univ.
July 13, 2020
-
COMMENTARY Diabetes Market Regaining Momentum with New Launches; First Oral GLP-1 a Game Changer?
July 13, 2020
-
BUSINESS Bayer Revving Up Cell Therapy Drive with First Focus on Parkinson’s, Japan Biz Also Eyed: R&D Chief
July 10, 2020
-
REGULATORY LDP Lawmakers Irked as Govt Stands Fast on Off-Year Re-Pricing/Survey Plan; Honebuto Text Tweak Unclear
July 10, 2020
-
REGULATORY Original Plan Remains Unchanged for Off-Year Drug Re-Pricing, Survey: Minister
July 9, 2020
-
BUSINESS Aducanumab Filing Completed in US; Talks with Japan/EU Regulators Ongoing
July 9, 2020
-
ORGANIZATION Mobile Pharmacy Van Set in Motion as Kumamoto Downpour Hits Local Stores, Some Wholesalers
July 8, 2020
-
ORGANIZATION Wholesaler Group Makes Emergency Plea against Off-Year Drug Price Survey
July 7, 2020
-
BUSINESS Ono to Fight Prof. Honjo’s Lawsuit over Opdivo Royalties
July 7, 2020
-
REGULATORY Japan Govt Likely to Stick to 2020 Off-Year Drug Re-Pricing Plan in Honebuto Paper
July 6, 2020
-
BUSINESS Maviret Shrivels, but AbbVie Japan in “Growth Mode” with Oncology, Immunology Drivers: Chief
July 3, 2020
-
ORGANIZATION COVID-19 Having “Serious Impact” on New Drug Development; JPMA Calls for Strong Systems for Emergencies
July 2, 2020
-
BUSINESS 26 Japan Drug Makers Log 4% Fall in Workforce as Downtrend Continues Unabated: FY2019 Securities Reports
July 1, 2020
-
BUSINESS AnGes Launches Clinical Trial for Coronavirus DNA Vaccine
July 1, 2020
-
REGULATORY Japan Approves Entresto, 4 Other Novartis Meds, Rybelsus, 1st Humira Biosimilar and More
June 30, 2020
-
BUSINESS Novo Japan Chief Sees 100 Billion Yen Target Achievable on Ozempic, Rybelsus
June 30, 2020
-
BUSINESS Pfizer Japan Boosting Biosimilar Sales Structure with Dedicated Unit, Ups Its Quality Pitch
June 29, 2020
-
BUSINESS AstraZeneca in Talks with Daiichi Sankyo, Meiji Group on COVID-19 Vaccine Supplies in Japan
June 29, 2020
ページ
Measures focusing on risk management should be necessary to prevent disruptions in API supplies, Prof. Hiroyuki Sakamaki of Kanagawa University…
Nearly a year after the introduction of the Ministry of Health, Labor and Welfare’s (MHLW) drug promotion guidelines in April…
Advancements in modified oligonucleotide technologies has been the key driver behind a spate of approvals in the oligonucleotide therapeutics space…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
A total of 51 new drugs joined the NHI price list in 2019, which are expected to generate combined peak sales of 373 billion yen, according to Jiho’s tally of data submitted to a key reimbursement policy panel. The relatively…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
Japan’s pharmaceutical industry has been in dire need of a shake-up, and as we continue to grapple with the COVID-19 pandemic, one thing is remarkably clear. It’s no longer business as usual, and we’re enjoying a front-row seat to some…